SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The firm's products include UroShield and PainShield. It operates through the following geographical segments: United States, Europe, Australia, India, Israel, and Other. The company was founded by Harold Jacob and Jona Zumeris in September 2003 and is headquartered in Tyler, TX.

NanoVibronix Inc

NAOV is trending following the grant of a new U.S. patent for its ENvue Medical subsidiary, which covers systems guiding medical device insertion using electromagnetic positioning. The community is discussing the stock's potential for further gains, consolidation patterns, and key price levels to watch, while also referencing the stock's low float and potential for a short squeeze.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending amid excitement surrounding its potential role in powering AI data centers and a new partnership with ABB, though some express concern about its high valuation and lack of revenue. Community discussions include potential price targets and comparisons to other nuclear companies, while others point to past news of share offerings as a cautionary sign. The stock's volatile price action is also a hot topic, with some traders looking to capitalize on short-term swings.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies is trending as investors discuss potential short squeezes amidst high short interest and anticipation of upcoming Fed rate decisions. Community members are highlighting institutional accumulation and technical indicators suggesting a breakout. Recent positive analyst ratings and the company's strategic positioning in the mortgage and real estate market with acquisitions like Redfin are also fueling the conversation.

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Helius Medical Technologies Inc - Ordinary Shares - Class A

Helius Medical Technologies Inc

HSDT is experiencing significant volatility, driven by speculation around a potential SOL treasury announcement. The community is actively discussing potential price targets and whether the stock is experiencing a pump and dump, while others highlight a possible incoming FDA submission. Some traders are comparing HSDT to other low float runners and weighing the potential for a short squeeze.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending as investors discuss its potential pivot towards AI/HPC, with some suggesting the company is undervalued compared to competitors like IREN. Community members are debating whether the company can successfully transition and capitalize on the AI/HPC trend, while others focus on short-term price movements and potential short squeezes.

Lulu's Fashion Lounge Holdings, Inc. engages in providing an online website for clothing. It offers retailing of women's clothing, shoes, and accessories. The company was founded in 1996 and is headquartered in Chico, CA.

Lulus Fashion Lounge Holdings Inc

LVLU is trending due to recent price movement and community speculation about a potential short squeeze, driven by its ultra-low float and high short interest. Traders are actively discussing technical setups, analyst price targets, and comparing it to other low-float runners. Some are awaiting further catalysts, such as news or filings, to fuel further momentum.

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics Inc

GLUE is trending due to a licensing agreement with Novartis potentially worth billions, leading to significant upfront payments and future royalties. Community members are debating whether to hold for long-term gains or take profits amidst discussions of short squeezes and potential price targets. The overall sentiment is bullish, driven by the news and the potential for substantial financial upside, though some caution against a possible pullback.

AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. Its product, RECELL system, is a device that enables healthcare professionals to produce a suspension of spray-on skin cells using a small sample of the patient's own skin for the treatment of acute thermal burns. The company was founded in December 1992 and is headquartered in Valencia, CA.

AVITA Medical Inc

AVITA Medical (RCEL) is trending following the CE Mark approval for its RECELL GO device, allowing commercialization across Europe and markets recognizing the CE Mark; the community is discussing the expanded market reach and potential revenue growth. Some are highlighting real-world data showing reduced hospital stays and cost savings with RECELL, while others express concerns about cash flow and dilution. Bullish sentiment centers on the company's growth potential in the wound care market and possible takeover.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Asset Entities Inc.

ASST is trending due to high short interest and a recent surge in volume, sparking discussions about a potential short squeeze. The community is actively debating the impact of the merger with Strive and its new Bitcoin treasury strategy on the stock's future. High borrowing fees and institutional ownership are also fueling speculation of a significant price movement.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as community members highlight the $WAGMI token and its potential, pointing to its launch on pump.fun and emphasizing community strength. Bullish sentiment is fueled by substantial SOL purchases from Galaxy Digital, with some analysts predicting a continued climb. Discussions also involve various Solana-based meme coins and projects gaining traction.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$NVAX Here&#39;s the article..

John Jacobs wasn’t interested when a recruiter approached him about the Novavax Inc. CEO job in 2022.

Jacobs was head of Pennsylvania’s Harmony Biosciences Holdings Inc. and within five years, had taken it from plucky startup to publicly traded firm with a $3 billion market cap. The company, which develops treatments for rare neurological diseases, was finally generating reliable revenue from its first commercial product, but Jacobs felt his work there wasn’t done. 

That changed after a discussion over lunch in the Philadelphia suburbs with Novavax board member Margaret McGlynn, the former longtime head of Merck’s global vaccines business.

Sammy Leonidas

Ivan

Drew

Framus Morrigan

Jing P18

paul

NotoriousMMX

Ciufy

Hae Reen

Tim Chron

Und Schwung

King Bob

Harold

MT. Guy

Crivit

M. Chart

Roger Luo

john l

Tee-Time

TopShelfStock

Peder Andersson

Macario

mirko

Ab Nas

inchainz

Bull74

Marcelina

$NVAX Thank you for sharing this. 

Great article. Company is in the midst of a chapter turning transformation. I’d rather be part of this rather than against it, especially under this leadership team. 

JJ is a visionary - I’ll give him that.

StockTwits for iOS

StockTwits For Android 

Novavax Inc

 Here's the article..

John Jacobs wasn’t interested when a recruiter approached him about the Novavax Inc. CEO job in 2022.

Jacobs was head of Pennsylvania’s Harmony Biosciences Holdings Inc. and within five years, had taken it from plucky startup to publicly traded firm with a $3 billion market cap. The company, which develops treatments for rare neurological diseases, was finally generating reliable revenue from its first commercial product, but Jacobs felt his work there wasn’t done. 

That changed after a discussion over lunch in the Philadelphia suburbs with Novavax board member Margaret McGlynn, the former longtime head of Merck’s global vaccines business.

Channel Guru

Novavax (NASDAQ: NVAX) had transformed from struggling clinical-stage biotech developing vaccines for respiratory diseases to heroic Covid-19 vaccine maker, credited with fighting to help end the public health emergency. Stanley Erck, Novavax’s chief executive of a dozen years, shepherded the company through that journey.

But the business had endured as much trouble as triumph, closing 2022 with serious financial issues, after flailing in efforts to capture a substantial slice of the Covid vaccine market. Novavax announced Erck’s retirement — and Jacobs’s appointment as his successor — in the new year.

“Even though the company was in more of a distressed position at the time, it was sitting on an amazing tech that could help change the world for the better, and ought to succeed,” Jacobs, 57, recalls thinking at the time.

Curious Investor

Paul J.

He took the job, and that thought has been driving his decision-making ever since.

The first few months were painful. Soon after taking the helm, Jacobs slashed hundreds of jobs, instituted a hiring freeze and cut spending across the company. He also took the risky step of issuing a going concern warning, sending a signal to investors and customers that the company, for all its attributes, was on thin ice. 

Those actions, not surprisingly, drove the stock into the ground, but there was a method to Jacobs’s madness. It was all part of a broader plan to simplify the company and position it for its next phase of growth, culminating in the blockbuster deal Novavax struck in the spring with French pharmaceutical giant Sanofi.

The $1.2 billion agreement could drive billions more to the local vaccine maker in future years. It positions Novavax to sustain itself long-term by handing its Covid vaccine work over to Sanofi, getting rid of the pandemic infrastructure it no longer needs and, once that’s done, returning to its roots as a lean biotech with a single charge: research and development. 

“It’s a big strategy shift,” says Mayank Mamtani, senior managing director and senior biotech research analyst for B. Riley Securities Inc., noting the vaccine business can be difficult for smaller players like Novavax. “Scientifically, they’re doing all the right things of going back to their core.&quot;

The $1.2 billion agreement could drive billions more to the local vaccine maker in future years. It positions Novavax to sustain itself long-term by handing its Covid vaccine work over to Sanofi, getting rid of the pandemic infrastructure it no longer needs and, once that’s done, returning to its roots as a lean biotech with a single charge: research and development. 

“It’s a big strategy shift,” says Mayank Mamtani, senior managing director and senior biotech research analyst for B. Riley Securities Inc., noting the vaccine business can be difficult for smaller players like Novavax. “Scientifically, they’re doing all the right things of going back to their core."

‘Back to our heart’

Jacobs’s life changed in 1977 after his parents divorced: His mother moved him and his brother from Long Island, New York, to Barbados.

They spent the next year living as Bajans rather than tourists, attending school and eating flying fish. His mom made oil paintings for locals, and sang and played guitar in the island’s hotels. Jacobs, then 9, spent every day in the Caribbean water and fell in-love with marine life.

It’s a passion that never went away. He took advanced high school biology classes, and entered college at the State University of New York at Plattsburgh as a bio major. He began studying the immune system, fascinated with how the body fights disease.

Then he took a marketing class with Nancy Church, then-chair of the Department of Marketing and Entrepreneurship in SUNY Plattsburgh’s School of Business and Economics. She became a mentor, recommending books and connecting him with an alum at Procter &amp; Gamble.

‘Back to our heart’

Jacobs’s life changed in 1977 after his parents divorced: His mother moved him and his brother from Long Island, New York, to Barbados.

They spent the next year living as Bajans rather than tourists, attending school and eating flying fish. His mom made oil paintings for locals, and sang and played guitar in the island’s hotels. Jacobs, then 9, spent every day in the Caribbean water and fell in-love with marine life.

It’s a passion that never went away. He took advanced high school biology classes, and entered college at the State University of New York at Plattsburgh as a bio major. He began studying the immune system, fascinated with how the body fights disease.

Then he took a marketing class with Nancy Church, then-chair of the Department of Marketing and Entrepreneurship in SUNY Plattsburgh’s School of Business and Economics. She became a mentor, recommending books and connecting him with an alum at Procter & Gamble.

He changed his major to business, with an ambition to work in health care — and to someday be a CEO.

“I think he likes to challenge himself,” Church says. “He has the people skills to get them all to rally around, and move in a direction that the company needs to go in.”

Still, little could have prepared him for the challenges he has faced at Novavax.

Novavax entered the Covid vaccine race when the coronavirus crisis began, quickly securing billions of dollars from government contracts and stock sales, ballooning its staff, getting its protein-based vaccine through clinical trials and landing it emergency use authorization. Sure, it fell behind mRNA competitors Moderna Inc., and Pfizer Inc. and BioNTech SE, but the achievement was, still, tremendous — and resulted in Novavax’s first product to market.

But Novavax sustained a dizzying array of twists and turns. Soon, the crisis eased and demand for vaccines waned. By early 2023, Novavax had billions of dollars in liabilities, pending arbitration with a global vaccine nonprofit, expenses it couldn’t sustain and revenue goals it couldn’t hit.

So Jacobs reorganized his executive team, creating a chief strategy officer position, tweaking the reporting hierarchy and reshuffling roles as longtime executives including Dr. Gregory Glenn, the R&amp;D leader behind Novavax’s Covid vaccine charge, retired.

But Novavax sustained a dizzying array of twists and turns. Soon, the crisis eased and demand for vaccines waned. By early 2023, Novavax had billions of dollars in liabilities, pending arbitration with a global vaccine nonprofit, expenses it couldn’t sustain and revenue goals it couldn’t hit.

So Jacobs reorganized his executive team, creating a chief strategy officer position, tweaking the reporting hierarchy and reshuffling roles as longtime executives including Dr. Gregory Glenn, the R&D leader behind Novavax’s Covid vaccine charge, retired.

He slashed the workforce by more than 30% and set out to offload real estate, such as the company’s Czech manufacturing plant. He crafted a plan to crawl out from the crushing mountain of debt.

By May of this year, an investment firm had launched a proxy fight against Novavax, pushing to oust a few board members and arguing that management failed to make the business as profitable as it should be. Within a few days, Novavax and Sanofi announced their agreement — which, to be sure, had been in the works for months. The investor backed off.

The impact was hardly immediate. Novavax reported $415 million in second-quarter revenue, a 2% drop year over year, the bulk of which came from the Sanofi deal. It’s projecting between $700 million and $800 million in revenue for this year, lower than earlier estimates.

It also ended the second quarter with $1.1 billion in cash, roughly double its total in December. And the strategy’s reveal further created renewed optimism. Before the deal’s announcement, Novavax’s stock was trading below $5; it has since largely remained above $11 and has climbed as high as $22.

“We had to stabilize the company to the point we have so far in order to have enough leverage to negotiate a good deal,” Jacobs says. “That deal then begets more credibility, more validation of our tech and the opportunity to do even more as we continue to reduce expenses and move back to our heart as an R&amp;D organization.”

‘Turning over every stone’

When Jacobs thinks back to his year in Barbados, one thing stands out more than the dolphins and coral: the poverty.

“We had to stabilize the company to the point we have so far in order to have enough leverage to negotiate a good deal,” Jacobs says. “That deal then begets more credibility, more validation of our tech and the opportunity to do even more as we continue to reduce expenses and move back to our heart as an R&D organization.”

‘Turning over every stone’

When Jacobs thinks back to his year in Barbados, one thing stands out more than the dolphins and coral: the poverty.

He remembers a dinner with Beatrice, the woman who cleaned his family’s home, and her daughter, whose college education his mother funded, he says. “We weren’t rich; we were just middle-class Americans, but there, our money went far.”

He remembers walking into their house, a wooden chattel home with a metal, corrugated roof, a single light bulb, no furniture and a shared, outdoor metal faucet for water, as he describes it. He remembers sitting on the floor and eating hand-made coconut cakes. And he remembers Beatrice, “the happiest woman I ever met, always smiling, loved her kids, laughing and sharing everything she had with us,” he says. “On the trip home, Mom said, ‘Never forget this.’”